NuProbe Collaborates with QIAGEN to Develop Diagnostics Tests for Cancer Indications

 NuProbe Collaborates with QIAGEN to Develop Diagnostics Tests for Cancer Indications

NuProbe Collaborates with QIAGEN to Develop Diagnostics Tests for Cancer Indications

Shots:

  • The collaboration leverages NuProbe’s BDA technology and QIAGEN’s SPE technology to develop NGS based cancer diagnostic tests for non-invasive liquid biopsy. Integration of both the technologies will enable an accurate & affordable analysis of DNA mutations with low variant allele fractions
  • The partners will initially focus on developing research use only products for clinical researchers in oncology and may further work on other commercial products in the future
  • Additionally, NuProbe has completed five CE IVD registrations for diagnostic products, including liquid biopsy mutation detection kits for the EGFR and BRAF genes

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: QIAGEN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post